Preserved in vitro metabolic and functional characteristics of double-dose apheresis platelet concentrates photochemically treated with amotosalen and ultraviolet A light

Abstract

Preview
Dear Sir,
The INTERCEPT™ Blood System (Cerus Europe BV, Amersfoort, The Netherlands) uses a combination of the psoralen derivate amotosalen and ultraviolet A (UVA) light to prevent pathogens and leucocytes from replicating and functioning1. A novel process allows for the production of two pathogen-inactivated therapeutic platelet units from one double dose (DD) apheresis collection in a single treatment. However, only limited data are available on the in vitro quality of such INTERCEPT-treated DD apheresis platelet units. [...]